IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
about
Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms?New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acidMonitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel diseaseImpact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose.Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism.Pharmacogenomics in the treatment of inflammatory bowel disease.Novel strategies in the thiopurine treatment of inflammatory bowel disease.Thiopurines in Crohn's disease, is there something new?Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia.Monitoring and safety of azathioprine therapy in inflammatory bowel disease.Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients.Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping.Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring
P2860
Q28486322-5DDA0802-4DCB-4E07-B711-1077BDEA95D7Q28538238-63479080-AAE7-4D05-A1DF-5A8DE5FE6197Q33941619-5385A689-96C2-4050-A10F-BCE5A269DCE5Q34549324-528784CD-422A-470F-AEF9-EBDA8D9C7B89Q36230695-F1992C30-C9D4-4DE7-AED7-2248D921A4CFQ36302849-8D8CCAC2-4870-4F35-B28E-386A490FC82BQ37710516-3C355745-CA95-4C93-9342-71054117BC11Q37764761-9C1E6EEE-D8C9-416E-8703-E1BB0A6E3DD5Q37797517-FBEAD27F-283B-48B9-968B-D802451C07F4Q37994062-567C0379-7931-4C12-896C-0B1B769C8CC3Q38134756-6161630F-B016-42E9-AC36-0B0B881A3D73Q38417177-41B3C271-AF56-409F-9EF4-21AB31B5C446Q39047242-EEF2396D-600D-408A-A99D-6A0EAEE5B9C2Q40582133-673B0379-F9D8-4809-BD2F-5DE784D3A9FCQ47344295-BE39B0E3-E520-4310-A719-30E5B49D7B51Q57817595-8C966076-6BCD-408C-BA34-EDCE16847834
P2860
IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
IMPDH activity in thiopurine-t ...... and metabolite concentrations.
@ast
IMPDH activity in thiopurine-t ...... and metabolite concentrations.
@en
type
label
IMPDH activity in thiopurine-t ...... and metabolite concentrations.
@ast
IMPDH activity in thiopurine-t ...... and metabolite concentrations.
@en
prefLabel
IMPDH activity in thiopurine-t ...... and metabolite concentrations.
@ast
IMPDH activity in thiopurine-t ...... and metabolite concentrations.
@en
P2093
P2860
P1476
IMPDH activity in thiopurine-t ...... and metabolite concentrations.
@en
P2093
Curt Peterson
Jan Taipalensuu
Sofie Haglund
P2860
P356
10.1111/J.1365-2125.2007.02985.X
P407
P50
P577
2007-07-27T00:00:00Z